Breast Cancer | Access and Reimbursement | Brazil and Mexico | 2017

Breast cancer affects thousands of individuals in Brazil and Mexico, and is managed with premium-priced agents, chemotherapy, and hormone therapy. In Mexico, coverage of treatment varies across the different healthcare programs; in Brazil, Herceptin is covered, but the uniqueness of public funding for oncology drugs makes public coverage of other treatments limited. The future will bring an influx of new drugs and biosimilars, and while both countries are eager to adopt new technologies, they have limited budgets—in an increasingly competitive market, only drugs that meet the clinical and economic expectations of both countries will achieve success. This A&R analysis provides key insights for navigating the HER2-positive breast cancer market in Brazil and Mexico, while adapting brand agents’ value message to payers’ and physicians’ needs and expectations in each country.


Clarivate’s Access and Reimbursement module for Breast Cancer in Brazil and Mexico explores the prescribing patterns for current HER2-targeted therapies, the potential impact of the anticipated arrival of novel therapies, and key national and regional market access factors that will shape the use of HER2-targeted therapies over the next two to three years. This content draws on insights from 100 surveyed physicians and from interviews with six payers in Brazil and Mexico, all of whom have influence at the regional or national level.

Markets covered: Brazil and Mexico

Primary research:

  • 100 oncologists/medical oncologists
  • 6 payers:
    • Brazil:
      • Pharmacist, specializing in public health. Member of the Department of Health of the State of São Paulo. Senior member of CCTIES (Coordinator of Science, Technology and Strategic Health Supplies) of the State of São Paulo. Close collaborator to MoH and CONITEC.
      • Clinical oncologist in reference hospitals in the public and private settings. Member of the Standardization Committee of New Technologies and responsible for elaboration of new protocols in public reference hospital. Member of the American Society of Clinical Oncology (ASCO).
      • Physician, Director of major HMO of the self-management type. Member of the Advisory Committee of the International Society for Pharmacoeconomics and Outcomes Research – ISPOR Latin America.
    • Mexico:
      • Head of the Department of Programming of Assets of Medical Supplies at ISSSTE.
      • Head of the Service of Medical Oncology at Medical Center of IMSS. Opinion leader in Mexico and Latin America. Member of the Society of Medical Oncology of IMSS. Member of National Coordination for the Creation of Diagnostic Guides – Therapeutics in the Oncology area of the IMSS. Active member of the Mexican Council of Oncology.
      • Oncologist, Chief of the Oncology and Radiotherapy Service of Hospital of the Secretary of Health. Member of the Mexican Council of Oncology.

Questions Answered in This Report:

  • What is the public and private healthcare coverage for premium-priced therapies for HER2-positive breast cancer, and how do payers’ policies and infrastructure influence access to specialized healthcare and treatments?
  • What are the current drivers and barriers for prescribing established premium-priced agents such as Herceptin, or newer agents such as Perjeta?
  • What will be the impact of biosimilars of trastuzumab in the prescription of Herceptin and other premium-priced agents?
  • What clinical benefits are physicians and payers looking for in emerging therapies such as margetuximab or neratinib, and what kind of savings in direct and indirect costs are payers looking for?
Login to access report